Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin

@article{Bambeke2009SafetyPO,
  title={Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin},
  author={Françoise Van Bambeke and Paul M. Tulkens},
  journal={Drug Safety},
  year={2009},
  volume={32},
  pages={359-378}
}
Moxifloxacin, a fluoroquinolone with potent activity against respiratory pathogens, is approved and considered as an alternative to β-lactams and macrolides for the treatment of acute bacterial sinusitis and lower respiratory tract infections. In this review, we critically examine its safety profile in comparison with other fluoroquinolones and other antibacterial classes sharing similar indications. Data were extracted from published clinical trials, meta-analyses, postmarketing studies… 
Moxifloxacin Safety
TLDR
The safety of moxifloxacin is essentially comparable to that of standard therapies for patients receiving the currently registered dosage and for whom contraindications and precautions of use (as in the product label) are taken into account.
Safety Considerations of Fluoroquinolones in the Elderly
TLDR
Overall, the specific adverse-effect profile of quinolones must be considered when they are chosen for treatment of bacterial infections because of physiological changes in renal function and when certain co-morbidities are present, some special considerations are necessary when elderly patients are treated with these drugs.
An Analysis of 14 Years of Clinical Data
TLDR
The safety profile of moxifloxacin versus comparators in the entire clinical database of the manufacturer was analyzed and fatal outcomes related to an AE or ADR were identified.
Safety Profile of the Fluoroquinolones
TLDR
Overall, it appears that levofloxacin is relatively well tolerated, with low rates of clinically important adverse events such as CNS toxicity, cardiovascular toxicity and dysglycaemia.
Fluoroquinolones in Community-Acquired Pneumonia
TLDR
Fluoroquinolone monotherapy may be associated with shorter hospital length of stay compared with β-lactam plus macrolide combination therapy, particularly in severe pneumonia or with high-dose therapy, and may have a role in healthcare-associated pneumonia when administered in combination with other antipseudomonal and anti-methicillin-resistant Staphylococcus aureus therapies.
The Safety of Levofloxacin in Tuberculosis Treatment Including Drug-induced Hepatotoxicity
TLDR
The effect of fluoroquinolones, including inhibiting DNA gyrase and increasing penetration into the infection loci, may enhance the bactericidal and sterilizing effect of the antituberculosis combination therapy.
Safety of Delafloxacin: Focus on Adverse Events of Special Interest
TLDR
The safety profile of delafloxacin is reviewed across clinical studies with an emphasis on the incidence of adverse events of special interest that are associated with fluoroquinolones.
Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones
TLDR
The lipoglycopeptide oritavancin is bactericidal against MRSA, vancomycin-resistant enterococci, and multiresistant Streptococcus pneumoniae, and proved effective and safe for the treatment of acute bacterial skin and skin structure infection (ABSSSI) upon administration of a single 1200 mg dose.
Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones
TLDR
The lipoglycopeptide oritavancin is bactericidal against MRSA, vancomycin-resistant enterococci, and multiresistant Streptococcus pneumoniae, and proved effective and safe for the treatment of acute bacterial skin and skin structure infection (ABSSSI) upon administration of a single 1200 mg dose.
Safety Profile of the Fluoroquinolones
TLDR
Patients did not show any statistically significant differences between 2005 and 2006 in terms of sex, age and number of concurrent medications, and data suggest that different fluoroquinolones are characterized by different rates and types of ADRs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 170 REFERENCES
The safety profile of moxifloxacin and other fluoroquinolones in special patient populations
  • P. Iannini
  • Medicine, Biology
    Current medical research and opinion
  • 2007
TLDR
Fluoroquinolones, are associated with rare, but clinically important, adverse events in special patient populations (including the elderly; those with hepatic, renal, or glycemic disorders; and those at risk for cardiovascular events); recognition of differences in the clinical efficacy and safety profiles of fluoroquolones inSpecial patient populations should lead to better antimicrobial agent selection.
Potential Interactions of the Extended-Spectrum Fluoroquinolones with the CNS
  • H. Lode
  • Biology, Medicine
    Drug safety
  • 1999
TLDR
Ongoing and future clinical studies will help to define the usefulness of the predictive models, as well as reveal the full CNS adverse event profile of these and other investigational fluoroquinolones.
Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections
TLDR
Once-daily oral moxifloxacin 400 mg was shown to be safe and effective in this trial for the treatment of respiratory tract infections of suspected bacterial origin in the clinical practice setting.
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
TLDR
Although studies are needed regarding its tolerability in at-risk patients with QT interval prolongation, available data suggest that moxifloxacin is likely to become a first-line therapy option for the treatment of community-acquired lower respiratory tract infections, particularly in areas where drug-resistant S. pneumoniae or H. influenzae are common.
Infectious Diseases: Safety Concerns with Fluoroquinolones
TLDR
Clinicians should be aware of possible alterations in blood glucose, QTc interval prolongation, seizures, phototoxicity, tendinopathy, or CDAD with the use of any fluoroquinolone, especially in patients with other risk factors for these conditions.
Moxifloxacin in respiratory tract infections
TLDR
Treatment guidelines should take into account the results of clinical trials with moxifloxacin in order to establish the role of this antimicrobial in the therapeutic arsenal against respiratory tract infections.
Comparative Tolerability of the Newer Fluoroquinolone Antibacterials
TLDR
Among the newer fluoroquinolones, clinically significant cardiac events are rare or absent but possible interactions in patients receiving other drugs capable of causing QT prolongation should be anticipated.
Antimicrobial safety: focus on fluoroquinolones.
  • R. Owens, P. Ambrose
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
The currently marketed quinolones are well tolerated, with safety profiles similar to those of other antimicrobial classes, although adverse effects are unusual, some, including tendinitis and CNS-related effects, are more common with quInolones than with other antimacterial classes.
Fluoroquinolone toxicity profiles: a review focusing on newer agents.
  • Benjamin A Lipsky, C. Baker
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
TLDR
Fluoroquinolones are safe in elderly, human immunodeficiency virus-infected, and neutropenic patients, but because of possible effects on articular cartilage, they are not currently recommended for children or pregnant women.
...
1
2
3
4
5
...